Experimental HIV Drugs
Experimental HIV Drugs
Experimental NRTI Apricitabine Demonstrates Good Antiviral Activity with No Serious Side Effects at 96 Weeks
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 20 March 2009 14:12
- Written by Avexa
While antiretroviral agents in novel classes have garnered the most attention in recent years, researchers continue to develop new drugs in existing classes. One such agent, the experimental nucleoside reverse transcriptase inhibitor (NRTI) apricitabine (formerly AVX754 and SPD754), continues to demonstrate good HIV suppression, no resistance, and a favorable side effects profile -- including minimal effect on blood lipids -- at 96 weeks. The lack of resistance is notable since apricitabine is structurally similar to lamivudine (3TC; Epivir) and emtricitabine (Emtriva).
Gilead Plans Clinical Trial of 4-in-1 Antiretroviral Combination Pill Containing Experimental Integrase Inhibitor Elvitegravir
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 20 January 2009 13:12
- Written by HIVandHepatitis.com
The development of combination pills containing 2 or more antiretroviral drugs has reduced the "pill burden" and improved the convenience of HIV treatment. As reported last week by the Bloomberg financial news service, Gilead is now planning studies of a new all-in-one "quad" antiretroviral pill containing the NRTIs tenofovir and emtricitabine (the same ones in Atripla and Truvada) plus the company's experimental integrase inhibitor elvitegravir and a boosting agent, making it the first-ever 4-drug antiretroviral coformulation.
ICAAC 2008: Investigational NNRTI RDEA806 Exhibits Promising Activity and Has High Barrier to Resistance
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 11 November 2008 12:55
- Written by Liz Highleyman
At the 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008) last week in Washington, DC, researchers presented data on several new antiretroviral agents in the pipeline, including an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) designated RDEA806, being developed by Ardea Biosciences.
ICAAC 2008: Zinc Finger Nuclease that Disables CCR5 Gene May Offer Potential New HIV Treatment Approach
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 18 November 2008 12:55
- Written by Liz Highleyman
It may be possible to create CD4 cells that are resistant to HIV infection by using zinc finger protein nucleases to disable the gene that encodes the CCR5 co-receptor, according to research presented at the 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008) last month in Washington, DC.
ICAAC 2008: Experimental NRTI Elvucitabine Suppresses HIV as well as Lamivudine at 48 Weeks
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 07 November 2008 12:55
- Written by HIVandHepatitis.com
While novel classes of antiretroviral drugs such as integrase inhibitors and CCR5 antagonists have received the most attention at recent HIV conferences, new agents in older classes also continue to make their way through the pipeline. At the 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008) last week in Washington, DC, researchers presented the latest data on elvucitabine (also known as ACH123,446), a cytosine analog nucleoside reverse transcriptase inhibitor (NRTI) being developed by Achillion Pharmaceuticals. Previous laboratory studies demonstrated potent in vitro activity against wild type HIV-1.
More Articles...
- ICAAC 2008: Long-term Safety of Investigational CCR5 Antagonist Vicriviroc in Treatment-experienced Patients
- AIDS 2008: Investigational Next-generation NNRTI Rilpivirine (TMC278) Demonstrates Potent Antiviral Activity at 96 Weeks in Treatment-naive Patients
- Monoclonal Antibody CCR5 Inhibitor PRO 140 Produces Long-lasting HIV Suppression in Single-dose Study
- AIDS 2006: TNX-355 Produces Significant Reduction in HIV Viral Load at 48 Weeks
Web Design and Development by